FDA Designation Announced For First Ever Oral Opioid Overdose Drug

FDA Awards Breakthrough Therapy Designation to Ensysce Biosciences' PF614-MPAR: A Leap Forward in Opioid Innovation.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant step forward for opioid research and development, Ensysce Biosciences Inc. (NASDAQ: ENSC) has announced that it has been granted a Breakthrough Therapy Designation (BTD) from the U.S Food and …